Skip to content Skip to sidebar Skip to footer

Newsletter

Ujjwal Maheshwari

Ujjwal Maheshwari is a Sydney-based financial writer at Stocks Down Under, where he has covered ASX and forex markets for over three years. He specialises in breaking down complex market developments into clear, accessible analysis for everyday investors.

Bachelor of Commerce (Finance), University of New South Wales (UNSW)

605 articles published

Gaming Stocks

Star Entertainment (ASX:SGR) Loses Another CEO: Is This Casino Stock Worth the Gamble?

Star Entertainment CEO Steps Down: What Next for SGR? Star Entertainment (ASX: SGR) shares rose 9.52% to close at A$0.12 on 17 December 2025, rebounding from A$0.105 the previous day after the company announced CEO Steve McCann had stepped down effective immediately. This marks the second time McCann has guided a troubled Australian casino through…

ByUjjwal MaheshwariDecember 17, 20250Comments

Energy Stocks

Karoon Energy (ASX:KAR) Drops to 6x P/E: Time to Buy the Dip?

Karoon Energy trades on 6x earnings as oil sentiment turns sour Karoon Energy (ASX: KAR) fell alongside the broader ASX energy sector this week as oil prices dropped toward one-month lows. The stock now trades around A$1.64, well below its 12-month high, even as the company keeps generating solid cash flows and buying back its…

ByUjjwal MaheshwariDecember 17, 20250Comments

Biotech Stocks

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is among the largest reported under Australia’s R&D Tax Incentive program. The finding means Recce's international clinical programs now qualify for the government's 43.5% tax rebate…

ByUjjwal MaheshwariDecember 17, 20250Comments

Biotech Stocks

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially life-threatening complication that affects up to 50 per cent of bone marrow transplant patients. With 65 participants now enrolled across clinical centres in the US,…

ByUjjwal MaheshwariDecember 16, 20250Comments

Gold Stocks

Medallion Metals’ $60M War Chest Sets Up 2026 Production Push- Is the Stock a Buy?

Medallion’s A$60M Raise Sets Up a 2026 Production Push Medallion Metals (ASX: MM8) has secured an A$60 million funding package, with Lion Selection Group committing A$5 million to the raise. For investors watching the junior gold developer space, this backing from one of Australia's most respected resource-focused investment groups signals strong institutional conviction in the…

ByUjjwal MaheshwariDecember 16, 20250Comments

Healthcare Stocks

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the past year, significantly outperforming the broader ASX, and now trades at a market capitalisation of around AUD 2.55 billion. For investors watching the healthcare space,…

ByUjjwal MaheshwariDecember 16, 20250Comments

Gold Stocks

Gorilla Gold (ASX: GG8) Adds 900% More Gold- Time to Buy or Cash Out?

Gorilla Gold surges after a 900% resource increase: what's next? Gorilla Gold (ASX: GG8) climbed another 5% yesterday after announcing a 900% jump in gold resources at its Comet Vale project in Western Australia. The resource has grown from around 96,000 ounces to 860,000 ounces, a remarkable result for a company that has quietly become…

ByUjjwal MaheshwariDecember 16, 20250Comments

Mining Stocks

Is South32 a Buy After Macquarie’s Upgrade? Here’s What Investors Need to Know

South32 (ASX: S32) climbed 3.6% on Friday after Macquarie upgraded the stock to Outperform with an A$3.70 price target. The broker pointed to improved returns and a favourable commodity backdrop as reasons for the bullish shift. For investors watching the ASX resources space, this upgrade comes at an interesting time. Silver has surged 119% year-to-date, copper…

ByUjjwal MaheshwariDecember 15, 20250Comments

Mining Stocks

Alcoa (ASX:AAI) Doubles From 52-Week Low: Buy the Breakout or Take Profits?

Alcoa’s (ASX: AAI) share price has almost doubled from its 52-week low of A$36.20 and is now trading around A$58. The stock hit a high of A$73.21 earlier this year before pulling back, but the business keeps getting stronger. Record smelter production, aluminium prices at their highest level in three years, and a major gallium…

ByUjjwal MaheshwariDecember 15, 20250Comments

Mining Stocks

BMC Minerals (ASX: BMC) Surges 25% on ASX Debut: Should You Buy After the IPO Pop?

BMC Minerals (ASX: BMC) made a strong entrance on the ASX on Friday, surging 25% from the A$2.00 IPO price to close at A$2.50. The oversubscribed A$100 million raising gives the company a market cap of roughly A$550 million, making it the largest non-gold mining IPO on the ASX since 29Metals in 2021. For investors,…

ByUjjwal MaheshwariDecember 15, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Ujjwal Maheshwari

Star Entertainment (ASX:SGR) Loses Another CEO: Is This Casino Stock Worth the Gamble?

Karoon Energy (ASX:KAR) Drops to 6x P/E: Time to Buy the Dip?

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Medallion Metals’ $60M War Chest Sets Up 2026 Production Push- Is the Stock a Buy?

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Gorilla Gold (ASX: GG8) Adds 900% More Gold- Time to Buy or Cash Out?

Is South32 a Buy After Macquarie’s Upgrade? Here’s What Investors Need to Know

Alcoa (ASX:AAI) Doubles From 52-Week Low: Buy the Breakout or Take Profits?

BMC Minerals (ASX: BMC) Surges 25% on ASX Debut: Should You Buy After the IPO Pop?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Ujjwal Maheshwari

Stocks in Spotlight

Add Your Heading Text Here